Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04427891
Other study ID # 2019-06114
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 21, 2021
Est. completion date December 2026

Study information

Verified date December 2022
Source Sahlgrenska University Hospital, Sweden
Contact Eva Haglind, MD, PhD
Phone +46705349088
Email eva.haglind@vgregion.se
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Perforated diverticulitis of the colon can be complicated by peritonitis, either purulent or fecal. Both are life threatening conditions requiring emergency surgery. The background in terms of reasons for inflammation (diverticulitis) and perforation to develop is unknown. In this study we focus on specific changes associated with inflammation, both in tissues and of fecal and mucosal microbiota.


Description:

A prospective study of abdominal fluid, periferal blood, tissues as well as feces in Patients (perforated diverticulitis with peritonitis undergoing emergency surgery, Group I), and in Controls (patients operated due to colorectal cancer, Group II; patients with mild diverticulitis not needing surgery, Group III). Immune acitvity in abdominal fluid and periferal blood by immunoassay of 92 individual proteins. mRNA expression of 96 specific genes in tissue samples. Quatification of bacterial diversity in feces and colon mucosa.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date December 2026
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Signs of perforated diverticulitis with peritonitis and decision to perform emergency surgery (Group I) - Signs of acute diverticulitis and no decision of emergency surgery (Group II) - Patients with colorectal cancer planned for elective surgery (Group III) Exclusion Criteria: - No surgery performed (Group I and III) - Withdrawn consent (any group)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Sweden Sahlgrenska University Hospital/Östra Gothenburg Västra Götaland Region

Sponsors (2)

Lead Sponsor Collaborator
Sahlgrenska University Hospital, Sweden Göteborg University

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary inflammatory response determination of levels of 92 proteins in abdominal fluid and blood index surgery (Groups I and II)/ emergency room (Group III)
Secondary inflammatory response in tissue RNA sequencing (96 spcific genes) in abdominal tissue index surgery (Groups I and II)/ emergency room (Group III)
Secondary microbiota composition PCR amplification, cloning and sequencing of genes index surgery (Groups I and II)/ emergency room (Group III)
See also
  Status Clinical Trial Phase
Recruiting NCT04220840 - The Damage Control Strategy for the Treatment of Perforated Diverticulitis of the Sigmoid Colon With Diffuse Peritonitis
Recruiting NCT01317485 - Laparoscopic Peritoneal Lavage or Resection for Generalised Peritonitis for Perforated Diverticulitis Phase 3
Completed NCT03332550 - A National Study of Clinical Results After Emergency Operation for Perforated Diverticulitis